23145-19-9

Basic information

• Product Name: 5-Methoxybenzofuran-2-carbaldehyde
• Synonyms: 5-Methoxy-2-benzofurancarbaldehyde;5-Methoxybenzofuran-2-carbaldehyde;5-methoxy-1-benzofuran-2-carbaldehyde
• CAS NO: 23145-19-9
• Molecular Formula: C₁₀H₈O₃
• Molecular Weight: 176.17
• Mol File: 23145-19-9.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 296 °C at 760 mmHg
• Flash Point: 132.8 °C
• Appearance: /
• Density: 1.24 g/cm³
• Vapor Pressure: 0.00147mmHg at 25°C
• Refractive Index: 1.619
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Methoxybenzofuran-2-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Methoxybenzofuran-2-carbaldehyde(23145-19-9)
• EPA Substance Registry System: 5-Methoxybenzofuran-2-carbaldehyde(23145-19-9)

Safety Data

• Hazardous Substances Data: 23145-19-9(Hazardous Substances Data)

Usage

General Description

5-Methoxybenzofuran-2-carbaldehyde is a chemical compound with the molecular formula C10H8O3. It is a benzofuran derivative and aldehyde, containing a methoxy group at the 5-position and an aldehyde functional group at the 2-position on the benzene ring. 5-Methoxybenzofuran-2-carbaldehyde is used in the synthesis of various organic compounds and is also of interest in the field of medicinal chemistry due to its potential pharmacological properties. Its unique structure and reactivity make it a valuable building block for the creation of diverse chemical structures in pharmaceutical research and development.

InChI:InChI=1/C10H8O3/c1-12-8-2-3-10-7(4-8)5-9(6-11)13-10/h2-6H,1H3

Upstream product

• 150-76-5 4-methoxy-phenol 
• 50551-56-9 ethyl 5-methoxybenzofuran-2-carboxylate 
• 1254062-17-3 (2-formyl-4-methoxyphenoxy)acetaldehyde diethyl acetal 
• 672-13-9 2-hydroxy-5-methoxybenzaldehyde 
• 10242-08-7 5-methoxybenzofuran-2-carboxylic acid 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 37603-26-2 2-(hydroxymethyl)-5-methoxy-benzo[b]furan 
• 23145-29-1 2-(2,2-Dimethoxy-ethoxy)-5-methoxy-benzaldehyde 

Downstream Products

• 139201-62-0 2-<2-(4-chlorophenyl)ethenyl>-5-methoxybenzofuran 
• 107092-74-0 5-Methoxy-2-[(Z)-2-nitro-3-(3,4,5-trimethoxy-phenyl)-propenyl]-benzofuran 
• 1429509-57-8 (E)-5-methoxy-2-(4-methylstyryl)benzofuran 
• 1429509-14-7 (Z)-5-methoxy-2-(4-methylstyryl)benzofuran 
• 138853-90-4 2-<2-(4-chlorophenyl)ethyl>-2,3-dihydro-6-(3-phenoxypropyl)-5-benzofuranol 
• 138853-86-8 2-<2-(4-chlorophenyl)ethyl>-2,3-dihydro-5-benzofuranol 
• 139201-63-1 2-<2-(4-chlorophenyl)ethenyl>-5-benzofuranol 
• 622863-32-5 4-(2-chlorophenyl)-9-methoxy-1H-[1]benzofuro[3,2-e]isoindole-1,3(2H)-dione 
• 622863-30-3 9-methoxy-4-phenyl-1H-[1]benzofuro[3,2-e]isoindole-1,3(2H)-dione 
• 622863-31-4 5-methoxy-2-[(E,Z)-2-(2-chlorophenyl)ethenyl]-1-benzofuran 
• 622863-29-0 5-methoxy-2-[(E,Z)-2-phenylethenyl]-1-benzofuran 

Relevant articles and documents

alpha-SYNUCLEIN AGGREGATE BINDING AGENT AND IMAGING METHOD

The present invention provides an α-synuclein aggregate binding agent that has high binding selectivity for an α-synuclein aggregate. The α-synuclein aggregate binding agent contains a compound represented by a formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: in the formula (I), R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; the ring A is a benzene or pyridine ring; the ring B is represented by the following formula (i) or (ii): R4 and R5 are each independently selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl.

In Vitro Antitumor Activity of Newly Synthesized Pyridazin-3(2H)-One Derivatives via Apoptosis Induction

Systemic toxicity associated with drug resistance continues to be the major obstacle to curative therapy of cancer. Tumor cell resistance to chemotherapeutic drugs often results in coordinate resistance to other structurally and functionally unrelated drugs and the subsequent development of cross resistance phenotype. Therefore, it seems necessary to identify new molecules as anticancer agents. In this process, we synthesized a series of new pyridazin-3(2H)-one derivatives and evaluated their antitumor potential. These cyclic molecules were synthesized and designed as a combination of benzofuran with pyridazinones. All final compounds have been characterized by spectral and elemental analyses to confirm successful synthesis reactions. To evaluate their anticancer activity, all derivatives were assessed against the human breast adenocarcinoma cell line (MCF-7) and the murine mastocytoma cell line (P815) using the methyl tetrazolium Test (MTT assay). The cytotoxic activity was found to be dose-dependent and the IC50 values of the synthesized compounds ranged from 14.5 to 40 μM against MCF-7 and from 35 to 82.5 μM against P815. At the same time, no cytotoxic activity was observed against normal cells. In order to investigate the molecular mechanism of the most cytotoxic product (6f), apoptosis induction was measured against MCF-7 cells. Using the annexin-V FITC staining technique, we showed that the cytotoxic effect of this product is associated with apoptosis induction.

TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS

The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.